Wockhardt Limited

Munish Talwar

Girish Kumar Jain

Ritesh Kapoor

Manoj Mashalkar

Sanjay Mate

Premchand Dalichandji Nakhat

Prashant Mandaogade

Mandar Kodgule

Yatendra Kumar Gupta

Inderjeetsingh Huda

Kasturi Roy

There is provided an extended release pharmaceutical composition comprising from about 200 mg to about 1000 mg of entacapone or salts thereof, optionally with other pharmaceutically acceptable excipients. The invention also provides an extended release pharmaceutical composition comprising triple combination of from about 30 mg to about 300 mg of levodopa, 10 mg to about 100 mg of carbidopa and 200 mg to about 1000 mg of entacapone or salts thereof, optionally with other pharmaceutically acceptable excipients. The invention also relates to process of preparation of such compositions.

Extended release pharmaceutical composition of entacapone or salts thereof

The invention relates to self emulsifying drug delivery system based compositions of rhein or diacerein, or salts or esters or prodrugs thereof which are bioequivalent to a 50 mg diacerein formulation marketed under the trade name Art 50&#xae;. The compositions exhibit no variability in fed and fasted state conditions. The compositions also result in significant reduction in side effects such as, soft stools effects as compared to Art 50&#xae;. The invention also relates to methods for preparing such compositions.

Self-emulsifying pharmaceutical compositions of rhein or diacerein

The present invention relates to single oral dose pharmaceutical compositions comprising a combination of entacapone, levodopa and carbidopa, or salts thereof along with one or more sugar alcohols, wherein the entacapone is co-micronized with one or more sugar alcohols. The composition of the invention exhibits bioequivalence to commercially available entacapone, levodopa and carbidopa combination formulation marketed under the trade name Stalevo200&#xae;. The invention also relates to processes for making such compositions.

Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability

There is provided a single unit oral dose pharmaceutical composition comprising a) levodopa or salts thereof from about 50 mg to about 300 mg in extended release form, b) carbidopa or salts thereof from about 10 mg to about 100 mg in extended release and c) entacapone or salts thereof from about 100 mg to about 1000 mg in immediate release form, optionally with other pharmaceutically acceptable excipients. The invention also relates to process of preparation of such compositions.

Single unit oral dose pharmaceutical composition comprising levodopa, carbidopa and entacapone or salts thereof

The invention relates to a taste masked pharmaceutical composition comprising duloxetine or pharmaceutically acceptable salts thereof. The invention also relates to processes for the preparation of such compositions. The invention further discloses an inclusion complex comprising duloxetine or pharmaceutically acceptable salts thereof with one or more cyclodextrin or derivatives thereof.

Pharmaceutical composition of duloxetine

The present invention relates to pharmaceutical compositions comprising entacapone or pharmaceutically acceptable salts thereof along with one or more sugar alcohols; wherein the entacapone is co-micronized with one or more sugar alcohols. The invention also relates to processes of making such compositions.

Growing community of inventors

Panchkula, India

Munish Talwar